Microbiota, chronic inflammation, and health: The promise of inflammatome and inflammatomics for precision medicine and health care
The terms “inflammatome” (holistic inflammation networks) and “inflammatomics” (a novel omics field) were proposed to decode dysbiosis-driven chronic inflammation and its disease links. Inflammatomics explores microbiota–immune crosstalk, particularly innate immune interactions, revealing how dysregulated microbial communities trigger chronic inflammation underlying disorders like inflammatory bowel disease, metabolic diseases, and neurodegeneration. This discipline transcends traditional inflammation paradigms by dissecting molecular pathways connecting dysbiosis to systemic inflammation, enabling early detection and precision interventions. It integrates evolutionary perspectives on host–microbe interactions, emphasizing the human body as a stress-sensitive “organ”. Challenges include standardizing inflammatome profiling, translating findings into clinical tools, and advancing multiomics technologies. By bridging microbial ecology, immunology, and systems medicine, inflammatomics holds a transformative potential to shift health care from reactive treatment to proactive, personalized prevention, targeting disease origins shaped by chronic inflammatome dysregulation. • Proposed “inflammatome” (holistic inflammation network) & “inflammatomics” (decoding dysbiosis-driven chronic inflammation). • Microbiota–immune crosstalk modulates inflammation and disease progression, informing targeted therapeutic strategies. • Chronic inflammation underlies metabolic/neurodegenerative disorders, revealing shared pathomechanisms. • Inflammatomics enables precision medicine via early detection, personalized interventions, and predictive biomarkers.
Authors
- Yujing Bi (ORCID: https://orcid.org/0000-0002-1228-9628)
- Fachao Zhi (ORCID: https://orcid.org/0000-0001-8674-4737)
- B. J. Yang Lee
- Fang He (ORCID: https://orcid.org/0000-0001-6912-6187)
- Seppo Salminen (ORCID: https://orcid.org/0000-0002-9737-7642)
- Xuesong Xiang
- Yafang Tan
- Xin Wang (ORCID: https://orcid.org/0000-0001-8051-1481)
- Ruifu Yang (ORCID: https://orcid.org/0000-0003-3219-7269)
- Yanping Han (ORCID: https://orcid.org/0000-0002-3762-1674)
- Huan Zhang (ORCID: https://orcid.org/0000-0002-2521-9370)
- Baoli Zhu (ORCID: https://orcid.org/0000-0001-5326-9503)
- Tong Wang (ORCID: https://orcid.org/0000-0002-2071-7530)
Institutions
- Hebei Medical University (CN)
- Turku University of Applied Sciences (FI)
- Chinese Center For Disease Control and Prevention (CN)
- Sichuan University (CN)
- Academy of Military Medical Sciences (CN)
- West China Hospital of Sichuan University (CN)
- NanoBioImaging (China) (CN)
- Institute of Microbiology (BY)
- Czech Academy of Sciences, Institute of Microbiology (CZ)
- ZheJiang Academy of Agricultural Sciences (CN)
- Institute of Microbiology (CN)
- National Institute for Occupational Health and Poison Control (CN)
- University of Chinese Academy of Sciences (CN)
- Southern Medical University (CN)
Publication Details
- Journal
- hLife
- Published
- 2025-04-15
- DOI
- https://doi.org/10.1016/j.hlife.2025.04.004
- Citations
- 5
- Primary Topic
- Gut microbiota and health
- Type
- article
- Field-Weighted Citation Impact
- 4.03
Funders
- National Natural Science Foundation of China